Patents by Inventor Ingrid Maurer-Fogy

Ingrid Maurer-Fogy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF
    Patent number: 7282483
    Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: October 16, 2007
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Patent number: 7264944
    Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 4, 2007
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF binding proteins
    Patent number: 7238776
    Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: July 3, 2007
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Publication number: 20020183485
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Application
    Filed: February 23, 2001
    Publication date: December 5, 2002
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Publication number: 20020169118
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Application
    Filed: July 3, 2001
    Publication date: November 14, 2002
    Applicant: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Publication number: 20020155112
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Application
    Filed: July 3, 2001
    Publication date: October 24, 2002
    Applicant: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAS coding for them
    Patent number: 6440693
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 27, 2002
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Publication number: 20020090676
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Application
    Filed: July 3, 2001
    Publication date: July 11, 2002
    Applicant: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF
    Patent number: 6417158
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 9, 2002
    Assignee: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Patent number: 6294352
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequence can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: February 1, 1995
    Date of Patent: September 25, 2001
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF Receptors, TNF binding proteins and DNAs coding for them
    Patent number: 6271346
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 7, 2001
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Patent number: 6221675
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF is receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 24, 2001
    Assignee: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Patent number: 5843791
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignee: Amgen Boulder Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Vascular anticoagulant proteins DNA which codes them, processer for preparing them and their use
    Patent number: 5837842
    Abstract: This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: November 17, 1998
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rudolf Hauptmann, Ingrid Maurer-Fogy, Gerhard Bodo, Peter Swetly, Christian Stratowa, Edgar Falkner, Gunther Adolf, Christiaan Maria Peter Reutelingsperger
  • Process and vector for expressing alpha-interferon in E. coli
    Patent number: 5710027
    Abstract: Methods and vectors for expressing interferon-alpha (IFN-.alpha.) proteins in E. coli are provided. Use of a vector comprising an IFN-.alpha. sequence fused to an E. coli heat-stable enterotoxin signal sequence (STII) under the control of the E. coli phosphatase (phoA) promoter affords high levels of correctly-folded and -processed, biologically active IFN-.alpha. polypeptides.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: January 20, 1998
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rudolf Hauptmann, Edgar Falkner, Gerhard Bodo, Tilman Voss, Ingrid Maurer-Fogy
  • Human manganese superoxide dismutase (hMn-SOD)
    Patent number: 5589371
    Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: December 31, 1996
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
  • Expression of mature proteinase 2A, the partial purification thereof and preparation of substrates having an inhibitory effect
    Patent number: 5559025
    Abstract: The invention relates to the expression of mature HRV proteinase 2A, the partial purification thereof and the preparation of substrates having an inhibitory effect.
    Type: Grant
    Filed: October 11, 1994
    Date of Patent: September 24, 1996
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Horst Ahorn, Ingrid Maurer-Fogy, Wolfgang Sommergruber, Andreas Zophel, Dieter Blaas, Ernst Kuchler, Hans-Dieter Liebig, Timothy Skern
  • Human manganese superoxide dismutase (hMn-SOD)
    Patent number: 5436162
    Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.
    Type: Grant
    Filed: September 15, 1992
    Date of Patent: July 25, 1995
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
  • Human manganese superoxide dismutase (hMn-SOD)
    Patent number: 5260204
    Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.
    Type: Grant
    Filed: September 15, 1992
    Date of Patent: November 9, 1993
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
  • Human manganese superoxide dismutase (hMn-SOD)
    Patent number: 5240847
    Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.
    Type: Grant
    Filed: March 11, 1988
    Date of Patent: August 31, 1993
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann